CTA
MRTX

Carillon Tower Advisers’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Carillon Tower Advisers’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$34.1M Sell
155,365
-15,849
-9% -$3.43M 0.21% 150
2020
Q3 		$28.4M Sell
171,214
-28,600
-14% -$3.91M 0.38% 79
2020
Q2 		$22.8M Hold
199,814
– – 0.18% 173
2020
Q1 		$14.4M Hold
199,814
– – 0.14% 222
2019
Q4 		$25.7M Buy
+199,814
New +$19.3M 0.17% 206

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Carillon Tower Advisers's MRTX Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Mirati Therapeutics, Inc. Common Stock (MRTX) stake by 9.3% in Q4 2020, selling an estimated $3.43M and leaving 155,365 shares worth $34.1M. The position accounts for 0.21% of the portfolio, ranked #150.

Carillon Tower Advisers first reported a position in MRTX in Q4 2019 and has held it in 5 quarters since. 284 funds tracked by Wall St. Rank hold MRTX as of Q4 2020.

  • Carillon Tower Advisers held 155,365 shares of Mirati Therapeutics, Inc. Common Stock worth $34.1M as of Q4 2020.
  • Carillon Tower Advisers sold 15,849 Mirati Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $3.43M.
  • Mirati Therapeutics, Inc. Common Stock made up 0.21% of Carillon Tower Advisers's portfolio in Q4 2020, its #150 holding.
  • Carillon Tower Advisers first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and has held it in 5 quarters since.
  • 284 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.